Zevra 治疗学公司以5 000万美元的价格向Compave出售了它的Serdex甲基苯酚甲酯投资组合,成为无债务和提振股票。 Zevra Therapeutics sold its serdexmethylphenidate portfolio to Commave for $50 million, becoming debt-free and boosting stock.

Zevra治疗股份在宣布出售包括AZSTARYS和KP1077在内的Serdex甲基苯甲酸酯投资组合后,于星期一上升4.56%至10.44美元,以5 000万美元的价格出售Compave治疗产品。 Zevra Therapeutics shares rose 4.56% to $10.44 on Monday after announcing the sale of its serdexmethylphenidate portfolio, including AZSTARYS and KP1077, to Commave Therapeutics for $50 million. 这笔交易解决了先前的诉讼并偿还了Zevra的6 300万美元长期贷款,使公司免除了债务,并使其能够专注于罕见的疾病治疗。 The deal, which resolves a prior lawsuit and repays Zevra’s $63 million term loan, makes the company debt-free and allows it to focus on rare disease treatments. 这项交易遵循了2019年的许可证协议,提高了Zevra的财务灵活性。 The transaction follows a 2019 licensing agreement and boosts Zevra’s financial flexibility. 股价收益反映了投资者的信心,而机构所有权仍保持在35.03%。 The stock’s gain reflects investor confidence, while institutional ownership remains at 35.03%.